Edgewise Therapeutics, Inc. — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 3/100
What the filing says
Kevin Koch (CEO) and Michael Nofi (CFO) filed standard Sarbanes-Oxley Section 302 and 906 certifications dated November 4, 2026, attesting to the accuracy of Edgewise's Q3 2026 10-Q filing and the effectiveness of internal controls and disclosure procedures. No material weaknesses, deficiencies, or fraud are disclosed. This is boilerplate executive certification required by regulation.
Why this rating
Routine regulatory filing exhibits; no operational, financial, or strategic changes disclosed. Standard compliance document.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.